Original Research • Systematic Review • Clinical Trial • Case Report • Short Communication • Methodology • Hypothesis • Commentary • Letter to Editor
________________________________________
Original Research
Original Research articles report novel experimental, analytical, or computational findings in botanical drug science. Acceptable topics include pharmacology, pharmacokinetics, toxicology, chemistry manufacturing and controls (CMC), formulation development, bioassay development, and mechanism-of-action studies. Manuscripts should present a clearly defined hypothesis or objective, rigorous methodology, reproducible results, and conclusions supported by the data. Both preclinical and clinical-stage investigations are welcome. Word limit: 6,000–8,000 words, excluding references, tables, and figures. Original research topics include:
- Pharmaceutical Analysis (CMC): Chromatographic fingerprinting (HPLC/GC-MS), metabolomics, authentication of raw materials, and batch-to-batch consistency studies.
- Pharmacology & Mechanisms: Identification of bioactive compounds, synergy studies, network pharmacology, and molecular target validation.
- Toxicology & Safety: Acute and chronic toxicity assessments, genotoxicity, and herb-drug interaction (HDI) studies.
- Pharmacokinetics (ADME): Absorption, Distribution, Metabolism, and Excretion studies of multi-component herbal mixtures.
________________________________________
Systematic Review / Meta-Analysis
Systematic Reviews and Meta-Analyses follow PRISMA or equivalent reporting guidelines to provide quantitative or structured qualitative synthesis of existing evidence on a focused research question. A registered protocol (e.g., PROSPERO) is strongly encouraged. The search strategy, inclusion/exclusion criteria, risk-of-bias assessment, and statistical methods (for meta-analyses) must be fully transparent and reproducible. Word limit: 8,000–12,000 words, excluding references.
The surge in AI-generated content has led to stricter scrutiny for review papers; they have to have truly unique insights into a clear knowledge gap to be considerred for publicaiton.
________________________________________
Clinical Study
Clinical study articles report the design, conduct, and outcomes of interventional studies evaluating botanical drug products in human subjects. All phases (Phase 1 through Phase 3) and pilot/feasibility studies are within scope. Manuscripts must comply with CONSORT reporting guidelines, provide the trial registration number (e.g., ClinicalTrials.gov), and include ethics approval documentation. Both positive and negative results are encouraged. Word limit: 6,000–8,000 words, excluding references, tables, and figures.
________________________________________
Case Report / Case Series
Case Reports describe a single clinical observation; Case Series describe two to ten cases sharing a common feature. Acceptable topics include novel therapeutic responses to botanical drug products, unexpected adverse events, rare presentations, pharmacokinetic anomalies, and drug–botanical interactions. Reports must include informed consent documentation and follow CARE reporting guidelines. Case Reports: 1,500–2,500 words. Case Series: 2,500–4,000 words.
________________________________________
Short Communication
Short Communications present preliminary, confirmatory, or limited-scope findings that contribute meaningfully to the field but do not require the depth of a full Original Research article. Examples include single-experiment validation studies, negative results of methodological importance, pilot data, and incremental advances in analytical or manufacturing methodology. Word limit: 2,000–3,000 words, including no more than 3 tables/figures combined.
________________________________________
Regulatory Science
Regulatory Science articles address the scientific, legal, and procedural frameworks governing botanical drug development and approval. Topics include FDA botanical drug guidance interpretation, CMC regulatory strategy, IND/NDA pathway analysis, international regulatory harmonization (EMA, NMPA, PMDA), pharmacopeial standards, and post-market requirements. Both empirical analyses of regulatory outcomes and analytical/strategic frameworks are accepted. Word limit: 4,000–7,000 words.
________________________________________
Technical Note
Technical notes describe novel or substantially improved analytical, manufacturing, or bioassay methods, procedural advances, instrument configurations, or validation datasets. Submissions must include sufficient detail for independent replication and should demonstrate the method's advantage over existing approaches. Technical notes: 1,500–5,000 words.
________________________________________
Commentary / Perspective
Commentary and Perspective articles offer expert interpretation of current developments, emerging trends, controversies, or policy shifts relevant to botanical drug science. These may be submitted or invited. Commentaries typically respond to a specific published article or event; Perspectives address broader themes. Both should present a clear, well-supported viewpoint while acknowledging alternative positions. Word limit: 2,000–3,500 words.
In the era of AI, this type of publication must provide deeper, more novel intellectual insights than. The jrection rate is high.
________________________________________
Letter to the Editor
Letters to the Editor provide concise commentary on articles published in Botanical Drugs within six months of publication, or brief observations of broad interest to the readership. Letters should present a focused point supported by evidence and may include up to 5 references and 1 table or figure. Authors of the original article will be invited to respond. Word limit: 800–1,200 words.